

1984-1985 INTERNSHIP, Department of Medicine, Stanford University Medical Center
 1985-1988 RESIDENCY, Department of Neurology and Neurological Sciences,
 Stanford University Medical Center
 1988-1989 FELLOWSHIP, Department of Neurology and Neurological Sciences,
 Stanford University Medical Center

PROFESSIONAL ORGANIZATIONS

American Academy of Neurology	International Stroke Society
American Medical Association	National Stroke Association
American Neurological Association	Stroke Council, American Heart Association
Bay Area Stroke Society	

HONORS AND AWARDS

1980 Dean's Academic and Service Award, University of California Irvine
 1982 National Board Examination Honors; Part I
 1984 Outstanding Student in Internal Medicine, University of California San Diego
 1984 E Baird Hasting Society (AOA equivalent at University of California San Diego)
 1984 National Board Examination Honors; Part II
 1985 National Board Examination Honors; Part III
 1989 Sandoz Award–Excellence in Neuropharmacology, Stanford University Medical Center
 1990 Lysia Forno Award for Teaching Excellence, Stanford University Medical Center
 1995 “Best Medical Specialists in North America–Cerebrovascular Disease” (national survey
 of physicians)
 1996 “Country's Best Heart and Stroke Doctors” (national survey of department chairs and
 section chiefs)
 1997-2009 “Best Bay Area Doctors” (survey of San Francisco Bay Area physicians)
 1998-2011 “Best Doctors in America” (national survey of physicians)
 1998-2007 “Best Doctors in Silicon Valley” (survey of San Jose physicians)
 2011 David G. Sherman Award: Outstanding Contributions to Stroke Research, American
 Heart Association
 2018 Baptist Health Innovators in Neuroscience Award
 2019 Distinguished Clinical Research Achievement Award (Top 3 clinical trials of 2018)
 Clinical Research Forum

NATIONAL CONSENSUS PANELS

1991 American College of Chest Physicians Expert Panel on Antithrombotic Therapy
 1993 Stroke Council of the American Heart Association Committee on Guidelines for the
 Management of TIAs
 1994 American College of Chest Physicians Expert Panel on Antithrombotic Therapy
 1996 American Heart Association Committee on Guidelines for Prevention of Stroke
 1998 4th European Stroke Consensus Panel–Management of Deteriorating Stroke
 1998 American College of Chest Physicians Expert Panel on Antithrombotic Therapy
 (Chairman, Cerebrovascular Diseases)
 1998 Stroke Council of the American Heart Association Committee on Guidelines for the
 Management of TIAs (Chairman)
 1999- present Stroke Treatment Industry Academic Roundtable (STAIR) (Chairman VII-X)

2000	American College of Chest Physicians Expert Panel on Antithrombotic Therapy (Chairman, Cerebrovascular Diseases and Atrial Fibrillation)
2002-2009	American College of Chest Physicians Expert Panel on Antithrombotic Therapy (Senior Editor)
2003	Stroke Council of the American Heart Association Committee on Guidelines for Stroke Prevention
2003-2008	American College of Chest Physicians Expert Panel on Antithrombotic Therapy (Chairman, Cerebrovascular Diseases)
2006-2011	Stroke Council of the American Heart Association Guidelines for Stroke Prevention

BOARD & COMMITTEE POSITIONS, NATIONAL / REGIONAL

1993-1995	American Heart Association Program Committee
1994	American Heart Association Stroke Task Force
1994-1995	American Heart Association Health Care Site Committee
1994-1997	American Heart Association Research Committee
1995-1997	American Heart Association Board of Directors, California Affiliate
1995-2002	Chairman, National Stroke Association Stroke Center Network
1996	Scientific Program Committee, Third North American Stroke Conference
1997-1999	Development Committee, Emergency Management of Stroke and Acute Myocardial Infarction, University of Massachusetts Medical Center
1998	Editorial Board, National Stroke Association, Stroke/Brain Attack Briefing
1998	Program Committee, 24th International Joint Conference on Stroke and Cerebral Circulation
1998-2000	Organizing Committee, 22nd Princeton Conference
1998	Editor, American Heart Association TIA module
1998-present	Examiner, American Board of Psychiatry and Neurology
1999	Program Committee, 25 th International Joint Conference on Stroke and Cerebral Circulation
1999-2003	Chairman, American Heart Association Operation Stroke
2000	Program Committee, 26 th International Joint Conference on Stroke and Cerebral Circulation
2001	Cerebrovascular Disease Topic Chair, 53 rd American Academy of Neurology Meeting
2003	Scientific Program Committee, World Stroke Conference
2011	Steering Committee, Princeton Conference

BOARD & COMMITTEE POSITIONS, STANFORD UNIVERSITY

1990-2003	Neurology and Neurological Sciences Voluntary Clinical Faculty Committee
1993-1994	Neurosurgery Chair Search Committee
1994	Stanford Neuropsychology Chief Search Committee
1995-1996	Stanford Medical Center Practice Advisory Group
1996-1998	General Clinical Research Center Advisory Committee
1996-1998	Clinical Trials Working Group
1996-1998	Medical Center Line Committee
1998	Epilepsy Director Search Committee
1998-2001	Medical Center Professorate Appointments and Promotions Committee
1999	Senator-at-Large (Alternate), Department of Neurology and Neurological Sciences
2001-2006	Stanford Hospital Capital Expenditures Committee
2001-2010	Chairman, Stroke Center Financial Development Project

2002-present Stanford Neurology/Neurosurgery Service Line Committee
2002-2006 Chairman, Stanford Neurology Clinical Practice Committee
2002 HIPPA Preparation Committee
2003 Department Senator, Department of Neurology and Neurological Sciences
2003 Medical Center Information Technology Committee
2007-2008 Human Subjects Committee
2003-2009 Chairman, Neurology and Neurological Sciences Adjunct Clinical Faculty Committee
2008-2013 Director, Stanford Neurology Grand Rounds
2008-2014 Program Director, Stanford Clinical Neurosciences Symposium

SCIENTIFIC REVIEW

NIH Grant Reviewer, 1994 – present
American Heart Association Grant Reviewer, 1994-1997
Abstract Grading Committee, International Conference on Stroke and Cerebral Circulation, 1996-2018
Abstract Grading Committee American Academy of Neurology, 2000-2001

JOURNAL REVIEW—ad hoc, 1989-Present

<i>Annals of Neurology</i>	<i>Journal of the Neurological Sciences</i>
<i>Annals of Internal Medicine</i>	<i>Journal of Stroke and Cerebrovascular Disease</i>
<i>Archives of Internal Medicine</i>	<i>Journal Watch Neurology</i>
<i>Archives of Neurology</i>	<i>Lancet and Lancet Neurology</i>
<i>CNS Drugs</i>	<i>Neurology</i>
<i>Cerebrovascular Disease</i>	<i>Neurology Network Commentary</i>
<i>Chest</i>	<i>New England Journal of Medicine</i>
<i>Journal of Critical Illness</i>	<i>Stroke</i>
<i>Journal of the American Medical Association</i>	

EDITORIAL BOARD — 2014-present

Stroke

TEACHING

Stanford University School of Medicine

Instructor, Preparation for Clinical Medicine
Lecturer, Neurology 205 (Clinical Neuroscience)
Lecturer, Clinical Neuropsychology
Lecturer, Cardiovascular Physiology 200
Lecturer, Primary Care Associate Program
Lecturer, Human Physiology
Lecturer, Health Research and Policy 251
Course Director, Discoveries and Debates Neuroscience NENS 25S1

University of California San Diego School of Medicine

Instructor, Physiology and Pharmacology

CLINICAL RESEARCH TRAINEES

Cerebrovascular Fellows

Joni M. Clark 1992-1994
David C. Tong 1993-1995

Midori A. Yenari 1993-1995
Helmi L. Lutsep 1995-1996
Vincent Thijs 1999-2001
Michael W. O'Brien 1996-1998
Andrew Woolfenden 1997-1998
Elaine J. Skalabrin 1998-2000

Bernard P. Chan 1998-2000

Philip R. Delio 1999-2001
Richard Bernstein 2000-2001

Shannon Kilgore 2002-2003
Amie Hsia 2002-2004
Maarten Lansberg 2003-2004

Neil Schwartz 2004-2005

Anna Finley Caulfield

Chitra Venkatsubramanian, MD 2005-2006

James Castle 2006-2007

Gabor Toth 2007-2008
May Kim 2007-2008

Archana Purushotham 2008-2010

Duane Campbell 2008-2010
Edgar Samaniego 2008-2010
Mikayel Grigoryan 2009-2010
Charlene Chen 2009-2011

Paul Singh 2010-2011
Amy Tai 2011-2012
Mohamed Teleb 2011-2012
Paul George 2012-2013
Christie Tung 2012-2014
Sharan Mann 2012-2013
Reza Pirsaheli 2012-2013
Nirali Vora 2013-2014
Pablo Bravo 2013-2014

Current Position

The Barrow Neurological Institute, Professor
California Pacific Medical Center, Medical Director
Stroke Care Center and Director CPMC Center
for Stroke Research
University of California San Francisco, Professor
Oregon Health Sciences University, Professor
Gasthuisberg University, Leuven, Belgium, Professor
Stroke neurologist, Redding, California
University of British Columbia, Associate Professor
University of Utah, Associate Professor and Director,
Stroke Center
National University of Singapore, Consultant and
Director Stroke Program
Stroke Neurologist, Santa Barbara, CA
Northwestern University, Professor and Director,
Stroke Center
Palo Alto VA Medical Center, Staff Physician
Georgetown University, Professor
Stanford Stroke Center, Stanford University Medical
Center, Associate Professor
Stanford Stroke Center, Stanford University Medical
Center, Professor
Stanford Stroke Center, Stanford University Medical
Center, Associate Professor
Stanford Stroke Center, Stanford University Medical
Center, Professor
Evanston Northwestern Healthcare Medical Group,
Chicago, IL, Associate Professor
Cleveland Clinic, Assistant Professor
University of Southern California, Assistant
Professor
National Institute of Neuro Sciences, India, Assistant
Professor
Director, Neurocritical Care, Tampa, Florida
Neurointerventional Neuroradiology, Ecuador
Neurointerventional Radiology, Los Angeles
Vascular Neurology, California Pacific Medical
Center, San Francisco
Assistant Professor, Mt Sinai, NY
Assistant Professor, Stanford Stroke Center
Interventional Neuroradiology, Phoenix
Assistant Professor, Stanford Stroke Center
Telemedicine Specialist, Specialists on Call
Associate Professor, University of British Columbia
Stroke/Neurocritical Care, Mercy Sacramento
Associate Professor, Stanford Stroke Center
Stroke/Neurocritical Care, Marshfield Clinic

Kyle Hobbs	2014-2105	Assistant Professor, Stanford Stroke Center
Mike Ke	2014-2015	California Pacific Medical Center
Jenny Tsai	2014-2016	Assistant Professor, University of Ottawa.
Sarah Lee	2015-2016	Assistant Professor, Stanford Stroke Center
Gracia, Mui	2015-2016	Assistant Professor, University of Connecticut
Ilana Spokoyny	2015-2016	California Pacific Medical Center
Catherine Legault	2016-2018	Assistant Professor, McGill
Sun Kim	2016-2017	Assistant Professor, SUNY
Divya Prabhu	2016-2017	Sequoia Hospital
Adam MacClellan	2017-2019	Stanford Stroke Center
Soo Kwon	2017-2018	Assistant Professor, U Alabama
Chris Southwood	2017-2018	Medical College of Wisconsin
Lironn Kraler	2018-2019	
Addason McCasalin	2018-2019	
Margy McCollum	2018-2019	

Post-doctoral Research Associates

Daniel Chang, MD	1996-1997
Maarten Lansberg, MD	1997-1999
Vincent Thijs, MD, PhD	1999-2001
Waturu Kakuda, MD	2004-2006
Jean-Marc Olivot, MD, PhD	2006-2008
Jun Lee, MD	2009-2010
Manabu Inoue, MD, PhD	2011-2013
Nishant Mishra, MD, PhD	2012-2013
Carlo Cereda, MD	2013-2014

Medical Scholars Students

Rudolfo E. Saenz	1989-1991
Alexandra J. Golby	1991-1992
Paul Chard	1995
Anita Wu	1997
Hayley Wheeler	2012-2013
Vaishnavi Rao	2018-present

Early Clinical Experience Students

James B. Brewer	1994
Annette A. Keochian	1994

SELECTED RECENT RESEARCH STUDIES

Project Title	Funding Source	Role on Project	Award Period
DEFUSE 3	NIH	PI	2019
StrokeNet Regional Coordinating Center	NIH	PI	2018
StrokeNet Imaging Core	NIH	PI	2018
SENSE 3	NIH	Co-investigator	2017
CRISP	NIH	Co-investigator	2016
iCAS	NIH	Co-investigator	2016
DEFUSE 2	NIH	PI	2012
PERFUSE 2	NIH	Co-investigator	2014
SENSE 2	NIH	Co-investigator	2011
NIH K24 grant	NIH	PI	2010
Improved PWI Methodology in Acute Clinical Stroke	NIH	Co-investigator	2006
DWI Assessment of Clinical Acute Stroke	NIH	Co-Investigator	6/01-4/05
Secondary Prevention of Small Subcortical Strokes	NIH	Co-Investigator	3/03-2/04
Phase II, Randomized, Pharmacokinetic, Dose Finding, and Dose Frequency Determination using rt-PA in Intraventricular Hemorrhage	NIH	Co-Investigator	1/04-12/07
Diffusion and Perfusion MRI to Assess Infarct Volume Status in Acute Stroke	Janssen Pharm	Principal Investigator	9/96-12/03
A Double-Blind, Randomized, Placebo-Controlled Study of Atorvastatin as Prevention of Cerebrovascular Events in Patients with a Previous Transient Ischemic Attack (TIA) or stroke	Parke-Davis	Principal Investigator	4/99-3/04
Long-term Treatment with Oral Thrombin Inhibitor H376/95, Compared to Warfarin as Stroke Prophylaxis in Patients with Atrial Fibrillation. An Open Follow-up Study	Astra Zeneca	Principal Investigator	11/99-6/04

Epidemiologic Study of Acute Ischemic Stroke	Genentech	Principal Investigator	2/00-7/04
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent TIA or Ischemic Stroke (MATCH)	Sanofi	Principal Investigator	5/01-10/03
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Escalating Dose Study of the Safety and Tolerability of SUN N4057 Administered for 72 hours by Continuous Intravenous Infusion in Successive Cohorts of Patients with Acute Ischemic Stroke	Suntory	Co-Investigator	6/02-12/03
A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients with Recent Ischemic Stroke	Fujisawa	Principal Investigator	11/02-5/04
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII(NovoSeven) in Acute Intracerebral Hemorrhage Project Title	Novo Nordisk Pharm	Co-Investigator	6/03-6/04
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate The Safety and Efficacy of The Starflex Septal Closure Transient Ischemic Attack Due To Presumed Paradoxical Embolism Through A Patient: Foramen Ovale	NMT Medical	Principal Investigator	11/03-10/06
A Randomized, Double-blind, Placebo-controlled, Multi center Study of the Effects of ONO-2506 Intravenous Infusion on the Amelioration of Neurological Damage and Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic Stroke	Ono Pharmaceuticals, Inc	Principal Investigator	11/03-11/05
Prevention Regimen for Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel + aspirin, with and without Micardis	B.I.P.I.	Principal Investigator	12/03-11/07
An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke	Aventis Pharm	Principal Investigator	12/03-7/05

FUNDED RESEARCH 1986-2005 (See NIH Biosketch for current grant support)

1986-1988	Clinical Investigator, Stanford Migraine Headache Study (Pfizer Labs).
1988-1989	Clinical Research Fellow, Novel Therapeutic Strategies for Cerebral Protection Against Ischemia (Stanford University).
1988-1990	Clinical Investigator, Boston Area Anticoagulation for Atrial Fibrillation Trial (National Heart, Lung, and Blood Institute).
1989-1991	Clinical Investigator, Department of Veterans Affairs Cooperative Study on Stroke Prevention in Nonvalvular Atrial Fibrillation (Veteran Affairs Cooperative Studies).
1989-1991	Principal Investigator, Pilot Studies of Oral Dextromethorphan in Human Brain Ischemia (National Institutes of Health).

1989-1991 Clinical Investigator, Incidence of Brain Ischemia During Cardiac Bypass Surgery (Hoffmann-LaRoche).

1990 Clinical Investigator, Vitamin E for the Treatment of Tardive Dyskinesia (National Institute of Mental Health).

1990-1992 Clinical Investigator, Transesophageal Echocardiography in Patients with Acute Stroke (DuPont Pharmaceuticals).

1991-1993 Principal Investigator, Dose Escalation Study of Intravenous Dextrophan for Acute Stroke (Hoffmann-LaRoche).

1991-1996 Principal Investigator, Thrombolytic Therapy in Acute Ischemic Stroke (Genentech).

1992-1993 Principal Investigator, Assessment of the Effects of Ticlopidine Hydrochloride on Lipoproteins (Syntex).

1993-1997 Principal Investigator, Warfarin/Aspirin Recurrent Stroke Study (National Institutes of Health).

1993-1997 Principal Investigator, Stroke Prevention in Atrial Fibrillation III Study (National Institutes of Health).

1994 Principal Investigator, Comparison of Duplex Ultrasound with Conventional Angiography in Patients with Carotid Stenosis (Stanford Stroke Center).

1994-1995 Consultant, Establishment of a NIH Stroke Data Archive (Phase I) (National Institutes of Health).

1994-1995 Principal Investigator, Safety and Tolerability of CGS-19755 in Patients with Acute Ischemic Stroke (CIBA-GEIGY).

1994-1996 Principal Investigator, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial of the Efficacy and Safety of Enlimomab (Anti-ICAM-I) for Treatment of Acute Ischemic Stroke (Boehringer-Ingelheim).

1994-1995 Principal Investigator, Patent Foramen Ovale in Cryptogenic Stroke (National Institutes of Health).

1994-1997 Principal Investigator, Antiphospholipid Antibody Study (National Institutes of Health).

1994-1995 Principal Investigator, Choice of Antithrombotic Therapy in Patients with Atrial Fibrillation (University Hospital Consortium).

1995 Co-Investigator, Comparison of Conventional Angiography with Magnetic Resonance Angiography for Patients with Vertebral/Basilar Insufficiency (Stanford Stroke Center).

1995-1996 Principal Investigator, Safety, Tolerability and Pharmacokinetics of ACEA 1021 in Patients with Acute Stroke (CoCensys).

1995-1998 Co-Investigator, Magnetic Resonance Evaluation of Acute Stroke (National Institutes of Health).

1996-1997 Principal Investigator, Lubeluzole Acute Stroke Trial (Janssen Pharmaceuticals).

1996-1997 Principal Investigator, Cerestat Acute Stroke Study (Boehringer-Ingelheim).

1996-1997 Co-Investigator, Cervene Acute Stroke Study (Baker-Norton Pharmaceuticals).

1996-1998 Principal Investigator, Diffusion and Perfusion MRI to Monitor Infarct Volume and Perfusion Status in Acute Stroke (Janssen Pharmaceuticals).

1996-1998 Co-Principal Investigator, Diffusion-Weighted MRI Assessment of Acute Clinical Stroke (National Institutes of Health).

1997-1998 Principal Investigator, APLAUD GPIIb/IIIa Antagonist Safety Study (SmithKline Beecham).

1997-1998 Co-Investigator, Glycine Antagonist in Neuroprotection (GAIN-2) (Glaxo Wellcome).

1997-1998 Principal Investigator, Phase IV Study of rt-PA treatment for acute ischemic stroke (Genentech).

1997-1998 Co-Investigator, Safety and Efficacy of Combination Therapy Using Lubeluzole and Activase in Ischemic Stroke (Janssen Pharmaceuticals).

1997-1998 Principal Investigator, Randomized, Double-Blind, Placebo-Controlled Trial of Fiblast (basic fibroblast growth factor) in Patients with Acute Stroke (Wyeth-Ayerst).

1997-1998 Co-Investigator, HU23F2G Anti-adhesion to Limit Cytotoxic Injury in Stroke (ICOS).
1997-1999 Co-Investigator, Diffusion and Perfusion MRI in Assessment of Acute Ischemic Stroke (National Institutes of Health).
1997-1998 Principal Investigator, A Prospective Study to Assess the Inter-rater Reliability in Acute Ischemic Stroke (Janssen Pharmaceuticals).
1997-1998 Principal Investigator, Stroke Presentation Survey (Genentech).
1997-1998 Principal Investigator, Basic Fibroblast Growth Factor Acute Stroke Trial (Wyeth-Ayerst).
1998-1999 Principal Investigator, Dose Escalation Study of the Safety of YM872 in Patients with Acute Ischemic Stroke (Yamanouchi USA).
1998-1999 Co-Investigator, Citicoline in Acute Stroke (Interneuron).
1998-1999 Principal Investigator, Clomethiazole Acute Stroke Studies (ischemic stroke, intracerebral hemorrhage, t-PA treated ischemic stroke) (Astra).
1998-2001 Co-Investigator, Warfarin Versus Aspirin for Stroke in Intracranial Disease (National Institutes of Health).
1997-1999 Co-Investigator, Use of Moderate Hypothermia in Severe Acute Ischemic or Hemorrhagic Stroke (Stanford Stroke Center).
1997-2000 Dose-Escalation Study of the Safety of YM872 in Patients with Acute Ischemic Stroke (Yamanouchi USA).
1998-2000 Principal Investigator, Vitamin Intervention of Stroke Prevention (National Institutes of Health).
1998-2000 Co-Investigator, Carotid Angioplasty and Stenting (Stanford Stroke Center).
1999-2000 Co-Investigator, Dose Response Trial of BMS-204352 in Patients with Acute Stroke (Bristol-Myers Squibb).
1999-2000 Principal Investigator, Phase II Study of Stroke Prevention in Atrial Fibrillation with H376/95 (Astra).
2000-2003 Principal Investigator, Phase III Study of Stroke Prevention in Atrial Fibrillation with H376/95 (Astra).
2000-2005 Principal Investigator, New MRI Techniques Prior to Intravenous t-PA Therapy Between 3-6 Hours After Stroke Onset (NIH).
(Includes 2 Supplements)
2001-2002 Principal Investigator, Combination Therapy with YM872 and t-PA for Acute Stroke (Yamanouchi USA).
2002-2004 Co-Investigator, Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven) for Preventing Early Hematoma Growth (Novo Nordisk Pharm).

NATIONAL OR INTERNATIONAL MULTICENTER TRIALS

Principal Investigator • Steering Committees • Protocol Development • Executive Committees

1991-1993 Dose Escalation Study of Intravenous Dextropropofol for Acute Stroke, Principal Investigator, (Hoffmann-LaRoche).
1991-1998 Thrombolytic Therapy in Acute Ischemic Stroke, Co-Principal Investigator, (Genentech).
1993-1997 Stroke Prevention in Atrial Fibrillation III Study, Stroke Adjudication Committee (National Institutes of Health).
1994-1995 Safety and Tolerability of CGS-19755 in Patients with Acute Ischemic Stroke, Lead Investigator, (CIBA-GEIGY).
1995-1996 Safety, Tolerability and Pharmacokinetics of ACEA 1021 in Patients with Acute Stroke, Principal Investigator (CoCensys).

1996-1997 Lubeluzole Acute Stroke Trial, Executive Committee (Janssen Pharmaceuticals).
1997-2000 Dose-Escalation Study of the Safety of YM872 in Patients with Acute Ischemic Stroke, Protocol Development Committee, (Yamanouchi USA).
1998-2003 International Study of Valsartan Antihypertensive Long-Term Use Evaluation, Endpoint Committee, (Novartis).
1998-1999 Standard Therapy with Alteplase for Treatment of Ischemic Stroke, Principal Investigator, (Genentech).
1999-2001 Study of LDP-01 in Acute Ischemic Stroke, Safety Committee, (Leukosite).
2000-2002 Phase III study of H376/95 for Stroke Prevention in Atrial Fibrillation, Executive Steering Committee, (Astra).
1999-2001 Epidemiologic Study of Ischemic Stroke, Principal Investigator, Executive Committee, (Genentech).
2000-2001 LaTIS neuro laser thrombolysis system, Safety Committee, (LaTIS)
2000-2003 Cerestat Acute Stroke Study, International Principal Investigator, (Boehringer Ingelheim)
2001-2003 YM 872 Phase IIb, Steering Committee, (Yamanouchi USA)
2002-2005 Desmotopase Acute Stroke Studies, DIAS and DEDAS Steering Committees (PAION)
2002-2004 FK 506 Acute Stroke Studies, Steering Committee, (Fujisawa)
2002-2005 Ono-2596 Acute Stroke Studies, Steering Committee, (Ono Pharmaceuticals)
2002-2005 Enoxaparin DVT Prevention Stroke Study, Steering Committee, (Aventis)
2003-2008 PRoFESS Stroke Prevention Study, International Steering Committee and National Coordinator, (Boehringer Ingelheim)
2006- 2011 Steering Committee, PhotoThera Stroke Trials (PhotoThera)
2007- 2010 Steering Committee, CLOSURE 1 Trial (NMT Medical)
2008- 2015 Steering committee Co-Chair, DIAS 3 / 4 Studies (Lundbeck)
2009-2011 DSMB member, WARCEF Study (NIH)
2011-2012 DSMB TREVO 2 study (Concentric)
2012-2015 Steering Committee, SWIFT PRIME (Concentric)
2013-2018 Executive Steering Committee, MARINER (J&J)
2015-2017 Chairman DSMB, PARFAIT Study (BMS)
2018- present Principal Investigator, TIMELESS Study (Genentech)

US PATENTS

Automated detection of arterial input function and/or venous output function voxels in medical imaging
Grant No.: 8837800 Issue Date: 9/16/2014

SELECTED PUBLICATIONS SINCE 2010

For full list of publications see: <https://med.stanford.edu/profiles/gregory-albers?tab=publications>

203. Albers GW. Stroke: more protection for patients with atrial fibrillation. *Lancet Neurol.* 2010; 9 (1): 2-4
204. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, Lees KR. Mismatch-based delayed thrombolysis: a meta-analysis. *Stroke.* 2010; 41 (1): e25-33
205. Lee J, Albers GW, Marks MP, Lansberg MG. Capsular warning syndrome caused by middle cerebral artery stenosis. *J Neurol Sci.* 2010 Sep 15;296(1-2):115-20.

206. Zaharchuk G, Straka M, Marks MP, Albers GW, Moseley ME, Bammer R. Combined arterial spin label and dynamic susceptibility contrast measurement of cerebral blood flow. *Magn Reson Med*. 2010 Jun;63(6):1548-56.
207. Castle J, Mlynash M, Lee K, Caulfield AF, Wolford C, Kemp S, Hamilton S, Albers GW, Olivot JM. Agreement regarding diagnosis of transient ischemic attack fairly low among stroke-trained neurologists. *Stroke*. 2010 Jul;41(7):1367-70.
208. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet*. 2010 May 15;375(9727):1695-703.
209. Schwartz NE, Albers GW. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. *Stroke*. 2010 Jun;41(6):1307-9.
210. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2010 Oct 21.
211. Olivot JM, Mlynash M, Kleinman JT, Straka M, Venkatasubramanian C, Bammer R, Moseley ME, Albers GW, Wijman CA; for the DASH investigators. MRI Profile of the Perihematomal Region in Acute Intracerebral Hemorrhage. *Stroke*. 2010 Nov;41(11):2681-2683.
212. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Furie KL, Giles MF, Labreuche J, Lavallée PC, Mas JL, Olivot JM, Purroy F, Rothwell PM, Saver JL, Sheehan OC, Stack JP, Walsh C, Kelly PJ. Addition of brain and carotid imaging to the ABCD(2) score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. *Lancet Neurol*. 2010 Nov;9(11):1060-9.
213. Olivot JM, Albers GW. Using advanced MRI techniques for patient selection before acute stroke therapy. *Curr Treat Options Cardiovasc Med*. 2010 Jun;12(3):230-9.
214. Giles MF, Albers GW, Amarenco P, Arsava MM, Asimos A, Ay H, Calvet D, Coutts S, Cucchiara BL, Demchuk AM, Johnston SC, Kelly PJ, Kim AS, Labreuche J, Lavallee PC, Mas JL, Merwick A, Olivot JM, Purroy F, Rosamond WD, Sciolla R, Rothwell PM. Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients. *Stroke*. 2010 Sep;41(9):1907-13.
215. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. *Stroke*. 2010 Dec;41(12):2872-83.
216. Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke.

217. Johnston SC, Albers GW, Gorelick PB, Cumbler E, Klingman J, Ross MA, Briggs M, Carlton J, Sloan EP, Vaince U. National stroke association recommendations for systems of care for transient ischemic attack. *Ann Neurol*. 2011 May;69(5):872-7.

218. Vora NA, Shook SJ, Schumacher HC, Tievsky AL, Albers GW, Wechsler LR, Gupta R. A 5-Item Scale to Predict Stroke Outcome After Cortical Middle Cerebral Artery Territory Infarction: Validation From Results of the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. *Stroke*. 2011 Mar;42(3):645-9.

219. Audebert HJ, Singer OC, Gotzler B, Vatankhah B, Boy S, Fiehler J, Lansberg MG, Albers GW, Kastrup A, Rovira A, Gass A, Rosso C, Derex L, Kim JS, Heuschmann P. Postthrombolysis hemorrhage risk is affected by stroke assessment bias between hemispheres. *Neurology*. 2011 Feb 15;76(7):629-36

220. Olivot JM, Albers GW. Diffusion-perfusion MRI for triaging transient ischemic attack and acute cerebrovascular syndromes. *Curr Opin Neurol*. 2011 Feb;24(1):44-9.

221. Schmiedeskamp H, Straka M, Newbould RD, Zaharchuk G, Andre JB, Olivot JM, Moseley ME, Albers GW, Bammer R. Combined spin- and gradient-echo perfusion-weighted imaging. *Magn Reson Med*. 2011 Nov 23.

222. De Silva DA, Churilov L, Olivot JM, Christensen S, Lansberg MG, Mlynash M, Campbell BC, Desmond P, Straka M, Bammer R, Albers GW, Davis SM, Donnan GA; EPITHET-DEFUSE Investigators. Greater effect of stroke thrombolysis in the presence of arterial obstruction. *Ann Neurol*. 2011 Oct;70(4):601-5.

223. Campbell BC, Costello C, Christensen S, Ebinger M, Parsons MW, Desmond PM, Barber PA, Butcher KS, Levi CR, De Silva DA, Lansberg MG, Mlynash M, Olivot JM, Straka M, Bammer R, Albers GW, Donnan GA, Davis SM; EPITHET-DEFUSE Investigators. Fluid-attenuated inversion recovery hyperintensity in acute ischemic stroke may not predict hemorrhagic transformation. *Cerebrovasc Dis*. 2011;32(4):401-5.

224. Albers GW, Fisher M. Improving the accuracy of perfusion imaging in acute ischemic stroke. *Ann Neurol*. 2011 Sep;70(3):347-9.

225. Giles MF, Albers GW, Amarenco P, Arsava EM, Asimos AW, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Johnston SC, Kelly PJ, Kim AS, Labreuche J, Lavallee PC, Mas JL, Merwick A, Olivot JM, Purroy F, Rosamond WD, Sciolla R, Rothwell PM. Early stroke risk and ABCD2 score performance in tissue- vs time-defined TIA: a multicenter study. *Neurology*. 2011 Sep 27;77(13):1222-8.

226. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL; STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. *Stroke*. 2011 Sep;42(9):2645-50.

227. Arac A, Brownell SE, Rothbard JB, Chen C, Ko RM, Pereira MP, Albers GW, Steinman L, Steinberg GK. Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. *Proc Natl Acad Sci U S A*. 2011 Aug 9;108(32):13287-92.

228. Campbell BC, Purushotham A, Christensen S, Desmond PM, Nagakane Y, Parsons MW, Lansberg MG, Mlynash M, Straka M, De Silva DA, Olivot JM, Bammer R, Albers GW, Donnan GA, Davis SM; EPITHET–DEFUSE Investigators. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. *J Cereb Blood Flow Metab.* 2012 Jan;32(1):50-6.
229. del Zoppo GJ, Sharp FR, Heiss WD, Albers GW. Heterogeneity in the penumbra. *J Cereb Blood Flow Metab.* 2011 Sep;31(9):1836-51.
230. Grigoryan M, Tung CE, Albers GW. Role of diffusion and perfusion MRI in selecting patients for reperfusion therapies. *Neuroimaging Clin N Am.* 2011 May;21(2):247-57
231. Olivot JM, Wolford C, Castle J, Mlynash M, Schwartz NE, Lansberg MG, Kemp S, Albers GW. Two aces: transient ischemic attack work-up as outpatient assessment of clinical evaluation and safety. *Stroke.* 2011 Jul;42(7):1839-43.
232. Kumar MA, Vangala H, Tong DC, Campbell DM, Balgude A, Eyingorn I, Beraud AS, Olivot JM, Hsia AW, Bernstein RA, Wijman CA, Lansberg MG, Mlynash M, Hamilton S, Moseley ME, Albers GW. MRI guides diagnostic approach for ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2011 Nov;82(11):1201-5.
233. Ogata T, Nagakane Y, Christensen S, Ma H, Campbell BC, Churilov L, Olivot JM, Desmond PM, Albers GW, Davis SM, Donnan GA; EPITHET and DEFUSE Investigators. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. *Stroke.* 2011 Jun;42(6):1596-601.
234. Lansberg MG, Lee J, Christensen S, Straka M, De Silva DA, Mlynash M, Campbell BC, Bammer R, Olivot JM, Desmond P, Davis SM, Donnan GA, Albers GW. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. *Stroke.* 2011 Jun;42(6):1608-14.
235. Mlynash M, Lansberg MG, De Silva DA, Lee J, Christensen S, Straka M, Campbell BC, Bammer R, Olivot JM, Desmond P, Donnan GA, Davis SM, Albers GW; DEFUSE-EPITHET Investigators. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. *Stroke.* 2011 May;42(5):1270-5.
236. Kleinman JT, Zaharchuk G, Mlynash M, Ogdie AA, Straka M, Lansberg MG, Schwartz NE, Kemp S, Bammer R, Albers GW, Olivot JM. Automated Perfusion Imaging for the Evaluation of Transient Ischemic Attack. *Stroke.* 2012 Jun;43(6):1556-60.
237. Andre JB, Zaharchuk G, Fischbein NJ, Augustin M, Skare S, Straka M, Rosenberg J, Lansberg MG, Kemp S, Wijman CA, Albers GW, Schwartz NE, Bammer R. Clinical Assessment of Standard and Generalized Autocalibrating Partially Parallel Acquisition Diffusion Imaging: Effects of Reduction Factor and Spatial Resolution. *Am J Neuroradiol.* 2012 Aug;33(7):1337-42.
238. Yoo AJ, Sheth KN, Kimberly WT, Chaudhry ZA, Elm JJ, Jacobson S, Davis SM, Donnan GA, Albers GW, Stern BJ, González RG. Validating Imaging Biomarkers of Cerebral Edema in Patients with Severe Ischemic Stroke. *J Stroke Cerebrovasc Dis.* 2012 Feb 8.

239. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *N Engl J Med*. 2012 Mar 15;366(11):991-9.
240. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA; on behalf of the American Heart Association Stroke Council. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2012 Aug 2.
241. Inoue M, Mlynash M, Straka M, Lansberg MG, Zaharchuk G, Bammer R, Albers GW. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. *Stroke*. 2012 Sep;43(9):2494-6.
242. Zaharchuk G, El Mogy IS, Fischbein NJ, Albers GW. Comparison of arterial spin labeling and bolus perfusion-weighted imaging for detecting mismatch in acute stroke. *Stroke*. 2012 Jul;43(7):1843-8.
243. MRI profile and response to endovascular reperfusion after stroke: the DEFUSE 2 study. MG Lansberg, M Straka, S Kemp, M Mlynash, LR Wechsler, T Jovin, MJ Wilder, HL Lutsep, TJ Czartoski, RA Bernstein, CWJ Chang, S Warach, F Fazekas, M Inoue, A Tipirneni, S A Hamilton, G Zaharchuk, MP Marks, R Bammer, GW Albers. *Lancet Neurol*. 2012 Oct;11(10):860-7.
244. Arterial spin labeling imaging findings in transient ischemic attack patients: comparison with diffusion- and bolus perfusion-weighted imaging. Zaharchuk G, Olivot JM, Fischbein NJ, Bammer R, Straka M, Kleinman JT, Albers GW. *Cerebrovasc Dis*. 2012;34(3):221-8.
245. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. von Kummer R, Albers GW, Mori E; DIAS Steering Committees. *Int J Stroke*. 2012 Oct;7(7):589-96.
246. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS; TREVO 2 Trialists. *Lancet*. 2012 Oct 6;380(9849):1231-40.
247. Kleinman JT, Mlynash M, Zaharchuk G, Ogdie AA, Straka M, Lansberg MG, Schwartz NE, Singh P, Kemp S, Bammer R, Albers GW, Olivot JM. *Int J Stroke*. 2012 Dec 11.
248. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Merwick Á, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Giles MF, Mas JL, Olivot JM, Purroy F, Rothwell PM, Saver JL, Sharma VK, Tsivgoulis G, Kelly PJ. *Stroke*. 2013 Oct;44(10):2814-20.
249. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. Wintermark M, Sanelli PC, Albers GW, Bello J, Derdeyn C, Hetts SW, Johnson MH, Kidwell C, Lev MH, Liebeskind DS, Rowley H, Schaefer PW, Sunshine JL, Zaharchuk G, Meltzer CC. *AJNR Am J Neuroradiol*. 2013 Nov-Dec;34(11):E117-27.
250. Wintermark M, Albers GW, Broderick JP, Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators. *Stroke*. 2013 Sep;44(9):2628-39.
251. Comparison of the response to endovascular reperfusion in relation to site of arterial occlusion. Lemmens R, Mlynash M, Straka M, Kemp S, Bammer R, Marks MP, Albers GW, Lansberg MG.

Neurology. 2013 Aug 13;81(7):614-8.

252. Apparent diffusion coefficient threshold for delineation of ischemic core. Purushotham A, Campbell BC, Straka M, Mlynash M, Olivot JM, Bammer R, Kemp SM, Albers GW, Lansberg MG. *Int J Stroke*. 2013 Jun 27.

253. MR RESCUE: is the glass half-full or half-empty? Parsons MW, Albers GW. *Stroke*. 2013 Jul;44(7):2055-7.

254. Impact of diffusion-weighted imaging lesion volume on the success of endovascular reperfusion therapy. Olivot JM, Mosimann PJ, Labreuche J, Inoue M, Meseguer E, Desilles JP, Rouchaud A, Klein IF, Straka M, Bammer R, Mlynash M, Amarenco P, Albers GW, Mazighi M. *Stroke*. 2013 Aug;44(8):2205-11.

255. Impact of recanalization, reperfusion, and collateral flow on clinical efficacy. Albers GW. *Stroke*. 2013 Jun;44(6 Suppl 1):S11-2.

256. Clinical outcomes strongly associated with the degree of reperfusion achieved in target mismatch patients: pooled data from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution studies. Inoue M, Mlynash M, Straka M, Kemp S, Jovin TG, Tipirneni A, Hamilton SA, Marks MP, Bammer R, Lansberg MG, Albers GW; DEFUSE 1 and 2 Investigators. *Stroke*. 2013 Jul;44(7):1885-90.

257. Imaging-based selection for intra-arterial stroke therapies. Morais LT, Leslie-Mazwi TM, Lev MH, Albers GW, Yoo AJ. *J Neurointerv Surg*. 2013 May;5 Suppl 1:i13-20.

258. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Tu HT, Campbell BC, Christensen S, Desmond PM, De Silva DA, Parsons MW, Churilov L, Lansberg MG, Mlynash M, Olivot JM, Straka M, Bammer R, Albers GW, Donnan GA, Davis SM; for the EPITHET-DEFUSE Investigators. *Int J Stroke*. 2013 Mar 12.

259. Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. Campbell BC, Christensen S, Parsons MW, Churilov L, Desmond PM, Barber PA, Butcher KS, Levi CR, De Silva DA, Lansberg MG, Mlynash M, Olivot JM, Straka M, Bammer R, Albers GW, Donnan GA, Davis SM; EPITHET and DEFUSE Investigators. *Ann Neurol*. 2013 Apr;73(4):510-9.

260. Early diffusion-weighted imaging and perfusion-weighted imaging lesion volumes forecast final infarct size in DEFUSE 2. Wheeler HM, Mlynash M, Inoue M, Tipirneni A, Liggins J, Zaharchuk G, Straka M, Kemp S, Bammer R, Lansberg MG, Albers GW; DEFUSE 2 Investigators. *Stroke*. 2013 Mar;44(3):681-5.

261. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Fisher M, Albers GW. *Ann Neurol*. 2013 Jan;73(1):4-9.

262. Selection for delayed intravenous alteplase treatment based on a prognostic score. Fulton RL, Lees KR, Bluhmki E, Biegert G, Albers GW, Davis SM, Donnan GA, Grotta JC, Hacke W, Kaste M, von Kummer R, Shuaib A, Toni D; VISTA Collaboration and ECASS, ATLANTIS, NINDS, and EPITHET Investigators, Alexandrov A, Bath PW, Claesson L, Curram J, Diener HC, Fisher M, Gregson B, Hennerici MG, Hommel M, Lyden P, Marler J, Muir K, Sacco R, Teal P, Wahlgren NG, Warach S, Weimar C. *Int J Stroke*. 2013 Jan 7.

263. The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study. Ogata T, Christensen S, Nagakane Y, Ma H, Campbell BC, Churilov L, Lansberg MG, Straka M, De Silva DA, Mlynash M, Bammer R, Olivot JM, Desmond PM, Albers GW, Davis SM, Donnan GA; EPITHET and DEFUSE Investigators. *Stroke*. 2013 Jan;44(1):87-93.
264. Correlation of AOL recanalization, TIMI reperfusion and TICI reperfusion with infarct growth and clinical outcome. Marks MP, Lansberg MG, Mlynash M, Kemp S, McTaggart R, Zaharchuk G, Bammer R, Albers GW; for the DEFUSE 2 Investigators. *J Neurointerv Surg*. 2013 Dec 18.
265. A score based on age and DWI volume predicts poor outcome following endovascular treatment for acute ischemic stroke. Liggins JT, Yoo AJ, Mishra NK, Wheeler HM, Straka M, Leslie-Mazwi TM, Chaudhry ZA, Kemp S, Mlynash M, Bammer R, Albers GW, Lansberg MG; DEFUSE 2 Investigators. *Int J Stroke*. 2013 Nov 10.
266. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. *Stroke*. 2014 Jan;45(1):281-3.
267. Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices. Saver JL, Jovin TG, Smith WS, Albers GW, et al; STAIR VIII Consortium. *Stroke*. 2013 Dec;44(12):3596-601.
268. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, Marks MP, Prabhakaran S, Kallmes DF, Fitzsimmons BF, Mocco J, Wardlaw JM, Barnwell SL, Jovin TG, Linfante I, Siddiqui AH, Alexander MJ, Hirsch JA, Wintermark M, Albers G, Cerebral Angiographic Revascularization Grading (CARG) Collaborators; STIR Revascularization working group; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. *Stroke*. 2013 Sep;44(9):2650-63.
269. Radiological examinations of transient ischemic attack. Tung CE, Olivot JM, Albers GW. *Front Neurol Neurosci*. 2014;33:115-22.
270. THRIVE score predicts outcomes with a third-generation endovascular stroke treatment device in the TREVO-2 trial. Flint AC, Xiang B, Gupta R, Nogueira RG, Lutsep HL, Jovin TG, Albers GW, Liebeskind DS, Sanossian N, Smith WS; TREVO-2 Trialists. *Stroke*. 2013 Dec;44(12):3370-5.
271. CT Perfusion Imaging in the Selection of Acute Stroke Patients to Undergo Emergent Carotid Endarterectomy. Devlin TG, Phade SV, Hutson RK, Fugate MW, Major GR 2nd, Albers GW, Sirelkhatim AA, Sapkota BL, Quartfordt SD, Baxter BW. *Ann Vasc Surg*. 2014 Sep 3.
272. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Leigh R, Jen SS, Hillis AE, Krakauer JW, Barker PB; STIR and VISTA Imaging Investigators. *Stroke*. 2014 Jul;45(7):2030-5.
273. Predictors of functional dependence despite successful revascularization in large-vessel occlusion strokes. Shi ZS, Liebeskind DS, Xiang B, Ge SG, Feng L, Albers GW, Budzik R, Devlin T, Gupta R, Jansen O, Jovin TG, Killer-Oberpfalzer M, Lutsep HL, Macho J, Nogueira RG, Rymer M, Smith WS, Wahlgren N, Duckwiler GR; Multi MERCI, TREVO, and TREVO 2 Investigators. *Stroke*. 2014 Jul;45(7):1977-84.
274. Endovascular treatment for stroke: when does the window for good outcome close?

Albers GW. *Lancet Neurol*. 2014 Jun;13(6):529-31.

275. Comparison of magnetic resonance imaging mismatch criteria to select patients for endovascular stroke therapy. Mishra NK, Albers GW, Christensen S, Marks M, Hamilton S, Straka M, Liggins JT, Kemp S, Mlynash M, Bammer R, Lansberg MG; Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 Investigators. *Stroke*. 2014 May;45(5):1369-74.

276. Aortic arch atheroma: a plaque of a different color or more of the same? George PM, Albers GW. *Stroke*. 2014 May;45(5):1239-40.

277. Angiographic outcome of endovascular stroke therapy correlated with MR findings, infarct growth, and clinical outcome in the DEFUSE 2 trial. Marks MP, Lansberg MG, Mlynash M, Kemp S, McTaggart RA, Zaharchuk G, Bammer R, Albers GW; DEFUSE Investigators. *Int J Stroke*. 2014

278. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Sheth KN, Taylor Kimberly W, Elm JJ, Kent TA, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, del Zoppo G, Marc Simard J, Stern BJ, Mandava P. *Neurocrit Care*. 2014 Aug;21(1):43-51.

279. Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort. Olivot JM, Mlynash M, Inoue M, Marks MP, Wheeler HM, Kemp S, Straka M, Zaharchuk G, Bammer R, Lansberg MG, Albers GW; DEFUSE 2 Investigators. *Stroke*. 2014 Apr;45(4):1018-23.

280. Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke. Marks MP, Lansberg MG, Mlynash M, Olivot JM, Straka M, Kemp S, McTaggart R, Inoue M, Zaharchuk G, Bammer R, Albers GW; Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 Investigators. *Stroke*. 2014 Apr;45(4):1035-9.

281. Early diffusion-weighted imaging reversal after endovascular reperfusion is typically transient in patients imaged 3 to 6 hours after onset. Inoue M, Mlynash M, Christensen S, Wheeler HM, Straka M, Tipirneni A, Kemp SM, Zaharchuk G, Olivot JM, Bammer R, Lansberg MG, Albers GW; DEFUSE 2 Investigators. *Stroke*. 2014 Apr;45(4):1024-8.

282. Secondary prevention of atherothrombotic or cryptogenic stroke. Tai WA, Albers GW. *Circulation*. 2014 Jan 28;129(4):527-31.

283. Patients with single distal MCA perfusion lesions have a high rate of good outcome with or without reperfusion. Lemmens R, Christensen S, Straka M, De Silva DA, Mlynash M, Campbell BC, Bammer R, Olivot JM, Desmond P, Marks MP, Davis SM, Donnan GA, Albers GW, Lansberg MG. *Int J Stroke*. 2014 Feb;9(2):156-9.

284. Carotid Artery Angioplasty versus Stenting in Acute Ischemic Stroke. Choudhri O, Gupta M, Feroze A, Albers G, Lansberg M, Do H, Dodd R, Marcellus M, Marks M. *J Neurointerv Surg*. 2014 Jul;6 Suppl 1:A18-9.

285. Pittsburgh outcomes after stroke thrombectomy score predicts outcomes after endovascular therapy for anterior circulation large vessel occlusions. Rangaraju S, Liggins JT, Aghaebrahim A, Streib C, Sun CH, Gupta R, Nogueira R, Frankel M, Mlynash M, Lansberg M, Albers G, Jadhav A, Jovin TG. *Stroke*. 2014 Aug;45(8):2298-304.

286. Interhospital variation in reperfusion rates following endovascular treatment for acute ischemic stroke. Liggins JT, Mlynash M, Jovin TG, Straka M, Kemp S, Bammer R, Marks MP, Albers GW, Lansberg MG; on behalf of the DEFUSE 2 Investigators. *J Neurointerv Surg*. 2014 Mar 24.

287. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brodt T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, Del Zoppo GJ, Baigent C, Sandercock P, Hacke W; for the Stroke Thrombolysis Trialists' Collaborative Group. *Lancet*. 2014 Aug 5. S0140-6736(14)60584-5

288. Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.

Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, Pereira VM, Cognard C, Yavagal DR, Saver JL.

Stroke. 2015 Oct;46(10):2786-94.

289. A benchmarking tool to evaluate computer tomography perfusion infarct core predictions against a DWI standard.

Cereda CW, Christensen S, Campbell BC, Mishra NK, Mlynash M, Levi C, Straka M, Wintermark M, Bammer R, Albers GW, Parsons MW, Lansberg MG.

J Cereb Blood Flow Metab. 2015 Oct 19.

290. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, Grotta J, Kaste M, Schwamm LH, Shuaib A; DIAS-3 Investigators.

Lancet Neurol. 2015 Jun;14(6):575-84.

291. Standards and Barriers in Acute Stroke Therapy: A Leap Forward in the Evolution of Endovascular Interventions for Stroke.

Albers GW, Halperin JL.

J Am Coll Cardiol. 2015 Dec 8;66(22):2506-9.

292. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report.

Albers GW, Bernstein RA, Brachmann J, Camm J, Easton JD, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Jaffer AK, Krieger DW, Passman R, Pines JM, Reed SD, Rothwell PM, Kowey PR.

J Am Heart Assoc. 2016 Mar 15;5(3):e002944.

293. Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials: Consensus Recommendations and Further Research Priorities.

Warach SJ, Luby M, Albers GW, Bammer R, Bivard A, Campbell BC, Derdeyn C, Heit JJ, Khatri P, Lansberg MG, Liebeskind DS, Majoie CB, Marks MP, Menon BK, Muir KW, Parsons MW, Vagal A, Yoo AJ, Alexandrov AV, Baron JC, Fiorella DJ, Furlan AJ, Puig J, Schellinger PD, Wintermark M; Stroke Imaging Research (STIR) and VISTA-Imaging Investigators.

Stroke. 2016 May;47(5):1389-98.

294. Identification of imaging selection patterns in acute ischemic stroke patients and the influence on treatment and clinical trial enrollment decision making.

Luby M, Warach SJ, Albers GW, Baron JC, Cognard C, Dávalos A, Donnan GA, Fiebach JB, Fiehler J, Hacke W, Lansberg MG, Liebeskind DS, Mattle HP, Oppenheim C, Schellinger PD, Wardlaw JM, Wintermark M.

Int J Stroke. 2016 Feb;11(2):180-90.

295. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS; SOCRATES Steering Committee and Investigators.

N Engl J Med. 2016 Jul 7;375(1):35-43.

296. ne-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke.

Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhã P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wong LK; TIAregistry.org Investigators.

N Engl J Med. 2016 Apr 21;374(16):1533-42.

297. Effect of endovascular reperfusion in relation to site of arterial occlusion.

Lemmens R, Hamilton SA, Liebeskind DS, Tomsick TA, Demchuk AM, Nogueira RG, Marks MP, Jahan R, Gralla J, Yoo AJ, Yeatts SD, Palesch YY, Saver JL, Pereira VM, Broderick JP, Albers GW, Lansberg MG; DEFUSE 2, IMS III, STAR, and SWIFT trialists; DEFUSE 2 IMS III STAR and SWIFT trialists.

Neurology. 2016 Feb 23;86(8):762-70

298. Magnetic resonance imaging-based endovascular versus medical stroke treatment for symptom onset up to 12 h. Wouters A, Lemmens R, Christensen S, Wilms G, Dupont P, Mlynash M, Schneider A, Laage R, Cereda CW, Lansberg MG, Albers GW, Thijs V; AXIS 2 and DEFUSE 2 study investigators.

Int J Stroke. 2016 Jan;11(1):127-33.

299. Inter-rater agreement analysis of the Precise Diagnostic Score for suspected transient ischemic attack. Cereda CW, George PM, Inoue M, Vora N, Olivot JM, Schwartz N, Lansberg MG, Kemp S, Mlynash M, Albers GW.

Int J Stroke. 2016 Jan;11(1):85-92.

300. Evolution of Volume and Signal Intensity on Fluid-attenuated Inversion Recovery MR Images after Endovascular Stroke Therapy.

Federau C, Mlynash M, Christensen S, Zaharchuk G, Cha B, Lansberg MG, Wintermark M, Albers GW. Radiology. 2016 Jul;280(1):184-92.

301. Ischemic core and hypoperfusion volumes predict infarct size in SWIFT PRIME.

Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, Pereira VM, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Baxter BW, Devlin TG, Lopes DK, Reddy VK, de Rochemont Rdu M, Singer OC, Bammer R, Saver JL.

Ann Neurol. 2016 Jan;79(1):76-89.

Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Král M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, Školoudík D, Steg PG, Touboul PJ, Uchiyama S,

Vicaut É, Wang Y, Wong LKS; TIAregistry.org Investigators. N Engl J Med. 2018 Jun 7;378(23):2182-2190.

Use of Imaging to Select Patients for Late Window Endovascular Therapy. Albers GW. Stroke. 2018 Sep;49(9):2256-2260

Endovascular thrombectomy in patients with large infarctions: reasons for restraint. Albers GW. Lancet Neurol. 2018 Oct;17(10):836-837.

Thrombectomy for Stroke with Selection by Perfusion Imaging. Albers GW, Marks MP, Lansberg MG. N Engl J Med. 2018 May 10;378(19):1849-1850. doi: 10.1056/NEJMc1803856.

Hypoperfusion Intensity Ratio Is Correlated With Patient Eligibility for Thrombectomy. Guenego A, Marcellus DG, Martin BW, Christensen S, Albers GW, Lansberg MG, Marks MP, Wintermark M, Heit JJ. Stroke. 2019 Apr;50(4):917-922

Validation and iteration of CT perfusion defined malignant profile thresholds for acute ischemic stroke. Keenan KJ, Christensen S, Inoue M, Mlynash M, Albers GW, Smith WS. Int J Stroke. 2019 Feb 22

Persistent Target Mismatch Profile >24 Hours After Stroke Onset in DEFUSE 3. Christensen S, Mlynash M, Kemp S, Yennu A, Heit JJ, Marks MP, Lansberg MG, Albers GW. Stroke. 2019 Mar;50(3):754-757.

Outcomes of Thrombectomy in Transferred Patients With Ischemic Stroke in the Late Window: A Subanalysis From the DEFUSE 3 Trial. Sarraj A, Mlynash M, Savitz SI, Heit JJ, Lansberg MG, Marks MP, Albers GW. JAMA Neurol. 2019 Feb 7.

DEFUSE 3 Non-DAWN Patients. Leslie-Mazwi TM, Hamilton S, Mlynash M, Patel AB, Schwamm LH, Lansberg MG, Marks M, Hirsch JA, Albers GW. Stroke. 2019 Mar;50(3):618-625.

Ischemic Core and Hypoperfusion Volumes Correlate With Infarct Size 24 Hours After Randomization in DEFUSE 3 Rao V, Christensen S, Yennu A, Mlynash M, Zaharchuk G, Heit J, Marks MP, Lansberg MG, Albers GW. Stroke. 2019 Mar;50(3):626-631.

Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial. Lansberg MG, Mlynash M, Hamilton S, Yeatts SD, Christensen S, Kemp S, Lavori PW, Gutierrez SO, Broderick J, Heit J, Marks MP, Albers GW; DEFUSE 3 Investigators. JAMA Neurol. 2019 Jan 28.

Penumbra imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Campbell BCV, Majoie CBLM, Albers GW, et al. for the HERMES collaborators. Lancet Neurol. 2019 Jan;18(1):46-55. Lancet Neurol. 2019 Mar;18(3):e2.

Hypoperfusion ratio predicts infarct growth during transfer for thrombectomy. Guenego A, Mlynash M, Christensen S, Kemp S, Heit JJ, Lansberg MG, Albers GW. Ann Neurol. 2018 Oct;84(4):616-620.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. N Engl J Med. 2018 Sep 20;379(12):1118-1127.

DEFUSE 3 Investigators. Endovascular Treatment in the DEFUSE 3 Study.Marks MP, Heit JJ, Lansberg MG, Kemp S, Christensen S, Derdeyn CP, Rasmussen PA, Zaidat OO, Broderick JP, Yeatts SD, Hamilton S, Mlynash M, Albers GW; Stroke. 2018 Aug;49(8):2000-2003.

More recent publications can be found at:

<https://med.stanford.edu/profiles/gregory-albers?tab=publications>